Skip to Main Content

Good morning from STAT reporter Andrew Joseph, filling in here for Mr. Pharmalot. We’ve recently been trying to experiment with just one cup of stimulation per day, but our current Case of the Mondays is really testing that commitment at the moment. As we wish you a stronger, perkier start to the week, we’ll leave you with a few tidbits. …

U.S. Sen. Bernie Sanders is figuring out just how far bullying drugmakers can take him, STAT writes. For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies before the panel with ambitious demands related to their pricing. After a few victories he’s claimed, he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight loss drugs. Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively.

advertisement

AstraZeneca is investing $1.5 billion in a manufacturing site in Singapore dedicated to the production of antibody drug conjugates, an advanced form of chemotherapy, the Financial Times reports. AstraZeneca’s investment in its first fully dedicated ADC site underlines the importance of the drug category to its future business and is the first time the drugmaker has built a manufacturing presence in Singapore. AstraZeneca said that the move was supported by Singapore’s Economic Development Board, but neither AstraZeneca nor the EDB disclosed what incentives it would receive from the Singaporean government. AstraZeneca has a portfolio of ADCs, including Enhertu, which is currently manufactured by its Japanese partner Daiichi Sankyo and generated more than $2.5 billion in sales last year.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.